Edge
Founded in 2017, Edge Medical Robotics develops single-port surgical robots that integrate AI to improve patient outcomes and hospital efficiency.
Secondary Market Price
Secondary Market Price
How Edge Measures Up
To help you manage your Edge equity, Prospect has run the company through our machine learning model.
Prospect Rating
TBD
We are still gathering data to evaluate Edge. Please check back soon for our rating on the company's projected worth four years from now.
Exit Risk
TBD
We are still gathering data on Edge to train our machine learning model. Check back soon for our exit risk rating for Edge!
Funding Stage
Series C
A Series C funding round means Edge is an established company that has already proven its business model and is now focused on scaling. For a potential employee, this offers more stability and security than an early-stage startup, along with a clear company direction.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Edge's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Edge Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Edge's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
EdgeMedical is a surgical robot platform company engaged in the development, research, and commercialization of single-port surgical robots. The company's systems integrate medical engineering, medical imaging, AI algorithms, and robot kinematics to assist in surgical processes, with the goal of improving patient outcomes and hospital efficiency. Founded in 2017 by Jianchen Wang, who is the Chairman and General Manager, the company was originally known as Shenzhen Jingfeng Medical Technology Co., Ltd. Headquartered in Shenzhen, China, EdgeMedical has raised a total of $317 million through multiple venture capital funding rounds and grew to 526 employees as of 2023. The company is currently profitable and generating revenue.
A significant recent development for the company is its registration for an initial public offering (IPO), which was announced on January 11, 2023. This move to go public represents the company's immediate future plan. EdgeMedical has also remained active in its research and development, filing several patents in 2023 for surgical robot systems and related technologies. This ongoing patent activity suggests a continued focus on expanding its portfolio of surgical robotics. The company has also been featured in industry research reports, such as the 2025 editions of 'Vertical Snapshot: Robotics' and 'AI VC Trends'.
- QED Investors
- 645 Ventures
- FJ Labs
- Eudemian Ventures
- Riverside Acci/Ventures
- Co-Founder, Joseph Denne
- Co-Founder, Will Lebens
- Co-Founder, Chris Mair
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Edge worth joining?
Deciding if a startup is worth joining requires careful evaluation of its potential, leadership, and your equity offer. Platforms like Prospect can help you assess a company's potential by providing data and models similar to those used by venture capitalists.
What should I do with my Edge stock?
Managing private company stock involves understanding your personal financial goals, tax implications, and the company's trajectory. You can use a service like Prospect to develop a personalized strategy for your equity, including when to exercise options or sell shares to maximize value.
Can you sell Edge stock?
Selling stock in a private company like Edge is possible, typically through secondary markets or company-organized liquidity events like tender offers. Tools from Prospect can help you determine tax-optimal shares to sell and navigate these opportunities.
How can I find the value of my Edge stock?
The value of private stock is typically determined by the company's most recent 409A valuation, fundraising rounds, and any secondary market activity. To get a forward-looking estimate, Prospect uses predictive models to project the future value of startup equity based on data used by top investors.
What is Edge's equity worth?
The precise worth of a private company's equity isn't public information and depends on factors like its latest valuation, growth, and overall market health. You can use Prospect's data-driven platform to better understand what your equity in a startup could be worth.
What is Edge's stock ticker symbol?
As a private company, Edge does not have a stock ticker symbol. Ticker symbols are only assigned to companies when they become publicly traded on a stock exchange.
Can I buy or sell Edge stock?
Selling private stock is sometimes possible through secondary markets or tender offers, while buying is typically limited to accredited investors during specific funding rounds. If you are an existing stockholder, platforms like Prospect offer tools to help you decide when and how much to sell for optimal tax outcomes.
What is the criteria to buy or invest in Edge stock?
Investing in a private startup is typically restricted to accredited investors or employees who receive equity as part of their compensation. If you are an employee with equity, Prospect provides resources to help you understand and manage its potential value.
